Barclays Adjusts PT and Estimates on Incyte (INCY); Better Than Expected Launch of Jakafi

July 13, 2012 2:45 PM EDT Send to a Friend
Get Alerts INCY Hot Sheet
Price: $62.91 +8.71%

Rating Summary:
    14 Buy, 3 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 23 | New: 17
Trade INCY Now!
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Incyte (NASDAQ: INCY) price target of $24.00 (from $19.00).

Analyst, Ying Huang, said, "We remain cautiously optimistic as we track Jakafi's launch progress. While Q1 2012 Jakafi sales of $19.3mn handily beat consensus, the Street appears to be more reserved for the remainder of 2012. Although we are lowering our Jakafi estimates, we remain positively biased for a better-than-expected launch in the near term. However, fundamentally we maintain our 2-EW rating, as we believe the value of the Jakafi and baricitinib franchises is fairly captured in the current stock price."

Huang lowers FY12 EPS estimate from $0.31 to $0.19 and FY13 from $0.52 to $0.41. However, he moderates Q2/FY12 Jakafi sales to $33M/$150M from $42M/$168M.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $25.60 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Barclays

Add Your Comment